Boule Diagnostics AB (CHIX:BOULs)
kr 26.3 (0%) Market Cap: 121.16 Mil Enterprise Value: 328.86 Mil PE Ratio: 40.63 PB Ratio: 0.72 GF Score: 43/100

Q2 2026 Boule Diagnostics AB Earnings Call Transcript

Jul 17, 2026 / 08:00 AM GMT
Release Date Price: kr26.3

Key Points

Positve
  • Boule Diagnostics AB (OSTO:BOUL) reported an improved overall gross margin of 2.2 percentage points compared to the previous year.
  • OEM sales showed recovery with organic growth and improved profitability compared to the same period last year.
  • Sales of instruments in the veterinary segment increased by 35% compared to the same period last year.
  • The company expanded its commercial presence with a new regional sales manager in Cameroon to accelerate growth in French-speaking West Africa.
  • Boule Diagnostics AB (OSTO:BOUL) successfully conducted regulatory audits by BSI, FDA, and Korean authorities without any remarks, confirming the strength of their quality management systems.
Negative
  • Group sales declined by 13%, primarily driven by negative currency effects and a moderate decline in organic growth.
  • The Diagnostics segment experienced a sales decline of 17.9%, impacted by currency headwinds and market turbulence.
  • Operating cash flow was negative at 1.5 million SEK, breaking the positive trend of the previous four quarters.
  • Liquidity remains hard-pressed, with a cash position of 20 million SEK and unused credit facilities of 6 million SEK.
  • High interest costs contributed to the negative cash flow for the quarter.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BOUL.ST - Boule Diagnostics AB
Q2 2026 Boule Diagnostics AB Earnings Call
Jul 17, 2026 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning, and welcome to our Quarter 2026 earnings calls.

My name is Michael Lavinkefeld. I'm the CFO of Bull Diagnostics.

And with me today, I have our new CEO, Johan Folkgunger, who joins us for his first investor call.

We will be recording this session, and after the formal presentation, we will open up for questions on the line and in the chat. With that, I hand it over to you, Johan.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Michael.

So, starting my new position on June 22nd, I have now been with the company for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot